Ideaya Advances Precision Oncology Pipeline with Positive Data from Three Cancer Drug Candidates
Ideaya presents promising data across three cancer drugs: darovasertib (76% response), IDE849 (58% response), and IDE397 combo (57% response).
Melanoma
Latest Post
Expert Panel: Optimizing Melanoma Brain Metastases Management with Modern Immunotherapy Approaches
Recent advances reshape management of melanoma brain metastases through combination immunotherapy and multidisciplinary approaches.
Nivolumab Plus Relatlimab vs. Nivolumab Alone for the Adjuvant Treatment of Completely Resected Stage III–IV Melanoma: Primary Results from RELATIVITY-098
NIVO + RELA did not result in significant RFS improvement vs NIVO alone as adjuvant...